Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

about

Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

P2860

Q39448172-ACE1EBC1-FDB8-47B4-B92D-8211F0EF3DB1 Q47110069-FDF03C00-8F9D-4251-9669-6F6171FAAE4D

P2860

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

Item

http://www.wikidata.org/entity/Q38946563

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Evaluation of the immunogenici ...... izumab during Phase I studies.

@en

type

Item

label

Evaluation of the immunogenici ...... izumab during Phase I studies.

@en

prefLabel

Evaluation of the immunogenici ...... izumab during Phase I studies.

@en

P1476

Evaluation of the immunogenici ...... izumab during Phase I studies.

@en

P2093

Akiko Harada

http://www.w3.org/2001/XMLSchema#string

Benjamin Lang

http://www.w3.org/2001/XMLSchema#string

Ippei Ikushima

http://www.w3.org/2001/XMLSchema#string

Joachim Stangier

http://www.w3.org/2001/XMLSchema#string

Paul A Reilly

http://www.w3.org/2001/XMLSchema#string

Stephan Glund

http://www.w3.org/2001/XMLSchema#string

Stephen Norris

http://www.w3.org/2001/XMLSchema#string

Steven Ramael

http://www.w3.org/2001/XMLSchema#string

Susumu Imazu

http://www.w3.org/2001/XMLSchema#string

Viktoria Moschetti

http://www.w3.org/2001/XMLSchema#string

P2860

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium

A specific antidote for dabigatran: functional and structural characterization

Dabigatran versus warfarin in patients with atrial fibrillation

Idarucizumab for Dabigatran Reversal

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets.

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Immunogenicity to biologics: mechanisms, prediction and reduction.

P304

1815-1825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13269

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28230262

http://www.w3.org/2001/XMLSchema#string

P932

5510069

http://www.w3.org/2001/XMLSchema#string

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

about

P2860

P2860

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932